A Phase 3 interventional study of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) and Placebo (Saline solution) in Respiratory Syncytial Virus (RSV), sponsored by MAXVAX Biotechnology Limited Liability Company. Recruiting at 8 sites in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by MAXVAX Biotechnology Limited Liability Company · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.
A total of 25000 adults aged 60 years and above will be enrolled, stratified into 60-69 and ≥70 years of age. All Participants will randomly receive investigational vaccine or placebo at a ratio of 1:1. Efficacy and safety will be assessed in all Participants, while immunogenicity will be assessed in a subset of 1200 Participants in a selected trial site.
MAXVAX Biotechnology Limited Liability Company is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A male or female can provide legal identification at the time of enrollment, and is 60 years of age or older (women are required to be infertile).
(Note: Women with infertility include those who have been menopausal or have undergone sterilization (including hysterectomy, bilateral salpingectomy, bilateral oophorectomy, etc.)
Exclusion Criteria:
Participants who meet any of the following exclusion criteria will not be allowed to enter the study (if the number of participants is not yet met, if the criteria described in "*" are met during screening, repeated screening may be performed)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single dose of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), by IM injection into the deltoid region of the arm.
Biological: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)
Participants will receive single dose of placebo, by IM injection into the deltoid region of the arm.
Biological: Placebo (Saline solution)
0.5 mL per dose
0.5 mL per dose
The first-time incidence rate per person-year of Lower Respiratory Tract Disease (LRTD).
A case caused by RSV-A and/or RSV-B as confirmed by Reverse Transcription-Polymerase Chain Reaction(RT-PCR).
Time frame: From 14 days after vaccination until the end of the first RSV epidemic season,assessed up to 12 months.
The first-time incidence rate per person-year of Acute Respiratory Illness (ARI).
A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.
Time frame: From 14 days after vaccination until the end of the first RSV epidemic season,assessed up to 12 months.
The first-time incidence rate per person-year of Severe Lower Respiratory Tract Disease (sLRTD).
A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.
Time frame: From 14 days after vaccination until the end of the first RSV epidemic season,assessed up to 12 months.
The first-time incidence rate per person-year of LRTD.
A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.
Time frame: After vaccination, during the second RSV epidemic season,assessed up to 12 months.
The first-time incidence rate per person-year of ARI.
A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.
Time frame: After vaccination, during the second RSV epidemic season,assessed up to 12 months.
The first-time incidence rate per person-year of sLRTD.
A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.
Time frame: After vaccination, during the second RSV epidemic season,assessed up to 12 months.
The first-time incidence rate per person-year of LRTD.
A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.
Time frame: From 14 days after vaccination until the end of the second RSV epidemic season,assessed up to 24 months.
The first-time incidence rate per person-year of ARI.
A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.
Time frame: From 14 days after vaccination until the end of the second RSV epidemic season,assessed up to 24 months.
The first-time incidence rate per person-year of sLRTD.
A case caused by RSV-A and/or RSV-B as confirmed by RT-PCR.
Time frame: From 14 days after vaccination until the end of the second RSV epidemic season,assessed up to 24 months.
Geometric Mean Titers (GMT) of Neutralizing Antibody against RSV-serotype A and RSV-serotype B.
Measured by Virus Neutralization Test.
Time frame: At 14 days,1,12,24 and 36 months after vaccination
Geometric Mean Fold Rise (GMFR) of Neutralizing Antibody against RSV-serotype A and RSV-serotype B
Measured by Virus Neutralization Test.
Time frame: At 14 days,1,12,24 and 36 months after vaccination
Geometric Mean Concentrations (GMC) of RSV-PreF specific IgG Antibody against RSV-serotype A and RSV-serotype B
Measured by ELISA.
Time frame: At 14 days,1,12,24 and 36 months after vaccination
GMFR of RSV-PreF specific IgG Antibody against RSV-serotype A and RSV-serotype B
Measured by ELISA.
Time frame: At 14 days,1,12,24 and 36 months after vaccination
Incidence, Intensity and Causality of adverse events(AEs)
An AE includes any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Time frame: Within 30 days after vaccination
Incidence, Intensity and Causality of solicited AEs
Solicited AEs include solicited local and general symptoms; Assessed solicited local AEs at injection site are pain, erythema, swelling, induration and itching; Assessed solicited general symptoms include fever, fatigue, headache, myalgia, nausea, vomiting, diarrhea, arthralgia and hypersensitivity.
Time frame: Within 7 days after vaccination
Incidence, Intensity and Causality of unsolicited AEs
An unsolicited AE covers any untoward medical occurrence in a clinical investigation participants temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: Within 30 days after vaccination
Incidence and Causality of Severe adverse events(SAEs)
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in persistent or significant disability/incapacity or are congenital anomaly/birth defect.
Time frame: Up to 12 months post vaccination
Incidence and Causality of Adverse event of special interest (AESI)
Adverse events of special interest include potential immune-mediated diseases and atrial fibrillation.
Time frame: Up to 12 months post vaccination
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jul 2026, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CHO cell
MAXVAX Biotechnology Limited Liability Company